0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Indolent Lymphoma - Epidemiology Forecast to 2028
Published Date: February 2019
|
Report Code: DELV-Epid-416
Home | Market Reports | Health | Health Conditions | Cancer
Indolent Lymphoma Epidemiology Forecast to 2028

Indolent Lymphoma - Epidemiology Forecast to 2028

Code: DELV-Epid-416
Report
February 2019
50 Pages
Delveinsight
Region: Global,
Description
Table of Content
Tables & Figures

DelveInsight's "Indolent Lymphoma - Epidemiology Forecast, 2028” report provides a comprehensive analysis of the Indolent Lymphoma epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028.

Markets Covered
• United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2016-2028

Indolent Lymphoma Epidemiology
The epidemiology section covers the historical, current as well as forecasted epidemiology for Indolent Lymphoma in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders’ views are also taken into account to provide a deep understanding of the Indolent Lymphoma outlook. It also includes the explanation of changing trends of epidemiology outlining the Indolent Lymphoma scenario.

Indolent Lymphoma Epidemiology Segmentation
The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Indolent Lymphoma thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope
• The report covers detailed overview of Indolent Lymphoma explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Indolent Lymphoma Report assesses the disease risk and burden and highlights the unmet needs
• It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths
• 10 Year Forecast
• 7MM Coverage
• Total Cases in Indolent Lymphoma

Key assessments
• Patient Segmentation in Indolent Lymphoma
• Indolent Lymphoma Risk & Burden
• Factors driving growth in a specific Indolent Lymphoma patient population

1. Report Introduction
2. Indolent Lymphoma Epidemiology Overview at a Glance
2.1. Patient Share Distribution of Indolent Lymphoma in 2016
2.2. Patient Share Distribution of Indolent Lymphoma in 2028
3. Disease Background and Overview: Indolent Lymphoma
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Indolent Lymphoma in 7MM
4.3. Total Prevalent/ Incident Patient Population of Indolent Lymphoma in 7MM – By Countries
5. Epidemiology of Indolent Lymphoma by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Indolent Lymphoma
5.1.3. Sub-Type Specific cases of the Indolent Lymphoma *
5.1.4. Sex- Specific Cases of the Indolent Lymphoma *
5.1.5. Diagnosed Cases of the Indolent Lymphoma
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Indolent Lymphoma
5.4.3. Sub-Type Specific cases of the Indolent Lymphoma *
5.4.4. Sex- Specific Cases of the Indolent Lymphoma *
5.4.5. Diagnosed Cases of the Indolent Lymphoma
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Indolent Lymphoma
5.5.3. Sub-Type Specific cases of the Indolent Lymphoma *
5.5.4. Sex- Specific Cases of the Indolent Lymphoma *
5.5.5. Diagnosed Cases of the Indolent Lymphoma
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Indolent Lymphoma
5.6.3. Sub-Type Specific cases of the Indolent Lymphoma *
5.6.4. Sex- Specific Cases of the Indolent Lymphoma *
5.6.5. Diagnosed Cases of the Indolent Lymphoma
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Indolent Lymphoma
5.7.3. Sub-Type Specific cases of the Indolent Lymphoma *
5.7.4. Sex- Specific Cases of the Indolent Lymphoma *
5.7.5. Diagnosed Cases of the Indolent Lymphoma
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Indolent Lymphoma
5.8.3. Sub-Type Specific cases of the Indolent Lymphoma *
5.8.4. Sex- Specific Cases of the Indolent Lymphoma *
5.8.5. Diagnosed Cases of the Indolent Lymphoma
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Indolent Lymphoma
5.9.3. Sub-Type Specific cases of the Indolent Lymphoma *
5.9.4. Sex- Specific Cases of the Indolent Lymphoma *
5.9.5. Diagnosed Cases of the Indolent Lymphoma
6. Unmet Needs of the Indolent Lymphoma
7. Appendix
8. Report Methodology
8.1. Sources
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight

List of Table:

Table 1: Total Prevalent/Incident Cases of the Indolent Lymphoma in 7MM
Table 2: Total Prevalent/Incident Cases of the Indolent Lymphoma in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Indolent Lymphoma in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Indolent Lymphoma in United States (2016-2028)*
Table 5: Sex- Specific Cases of the Indolent Lymphoma in United States (2016-2028)*
Table 6: Diagnosed Cases of the Indolent Lymphoma in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Indolent Lymphoma in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Indolent Lymphoma in Germany (2016-2028) *
Table 9: Sex- Specific Cases of the Indolent Lymphoma in Germany (2016-2028) *
Table 10: Diagnosed Cases of the Indolent Lymphoma in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Indolent Lymphoma in France (2016-2028)
Table 12: Sub-Type Specific cases of the Indolent Lymphoma in France (2016-2028) *
Table 13: Sex- Specific Cases of the Indolent Lymphoma in France (2016-2028) *
Table 14: Diagnosed Cases of the Indolent Lymphoma in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Indolent Lymphoma in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Indolent Lymphoma in Italy (2016-2028) *
Table 17: Sex- Specific Cases of the Indolent Lymphoma in Italy (2016-2028) *
Table 18: Diagnosed Cases of the Indolent Lymphoma in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Indolent Lymphoma in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Indolent Lymphoma in Spain (2016-2028) *
Table 21: Sex- Specific Cases of the Indolent Lymphoma in Spain (2016-2028) *
Table 22: Diagnosed Cases of the Indolent Lymphoma in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Indolent Lymphoma in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Indolent Lymphoma in UK (2016-2028) *
Table 25: Sex- Specific Cases of the Indolent Lymphoma in UK (2016-2028) *
Table 26: Diagnosed Cases of the Indolent Lymphoma in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Indolent Lymphoma in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Indolent Lymphoma in Japan (2016-2028) *
Table 29: Sex- Specific Cases of the Indolent Lymphoma in Japan (2016-2028) *
Table 30: Diagnosed Cases of the Indolent Lymphoma in Japan (2016-2028)

List of Figure:

Figure 1: Total Prevalent/Incident Cases of the Indolent Lymphoma in 7MM
Figure 2: Total Prevalent/Incident Cases of the Indolent Lymphoma in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Indolent Lymphoma in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Indolent Lymphoma in United States (2016-2028)*
Figure 5: Sex- Specific Cases of the Indolent Lymphoma in United States (2016-2028)*
Figure 6: Diagnosed Cases of the Indolent Lymphoma in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Indolent Lymphoma in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Indolent Lymphoma in Germany (2016-2028) *
Figure 9: Sex- Specific Cases of the Indolent Lymphoma in Germany (2016-2028) *
Figure 10: Diagnosed Cases of the Indolent Lymphoma in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Indolent Lymphoma in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Indolent Lymphoma in France (2016-2028) *
Figure 13: Sex- Specific Cases of the Indolent Lymphoma in France (2016-2028) *
Figure 14: Diagnosed Cases of the Indolent Lymphoma in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Indolent Lymphoma in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Indolent Lymphoma in Italy (2016-2028) *
Figure 17: Sex- Specific Cases of the Indolent Lymphoma in Italy (2016-2028) *
Figure 18: Diagnosed Cases of the Indolent Lymphoma in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Indolent Lymphoma in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Indolent Lymphoma in Spain (2016-2028) *
Figure 21: Sex- Specific Cases of the Indolent Lymphoma in Spain (2016-2028) *
Figure 22: Diagnosed Cases of the Indolent Lymphoma in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Indolent Lymphoma in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Indolent Lymphoma in UK (2016-2028) *
Figure 25: Sex- Specific Cases of the Indolent Lymphoma in UK (2016-2028) *
Figure 26: Diagnosed Cases of the Indolent Lymphoma in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Indolent Lymphoma in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Indolent Lymphoma in Japan (2016-2028) *
Figure 29: Sex- Specific Cases of the Indolent Lymphoma in Japan (2016-2028) *
Figure 30: Diagnosed Cases of the Indolent Lymphoma in Japan (2016-2028)

SELECT A FORMAT
Added to Cart

Electronic (PDF)
$3250
This license allows only one user to access the PDF.

Electronic (PDF)
$6500
This license allows all the users of an enterprise residing in one location to access the PDF

Electronic (PDF)
$9750
This license allows all the employees of an enterprise to access the PDF.
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
Nano String

RELATED REPORTS

Global Neuroendocrine Tumor NET Treatment Key Trends and Opportunities to 2027
Global Neuroendocrine Tumor (NET) Treatment Key Trends and Opportunities to 2027

120 Pages
Type: Report
Code: QYRE-Auto-32K8025
Sat Dec 04 00:00:00 UTC 2021

Add to Cart

Add to Cart

Global Tumor Infiltrating Lymphocyte TIL Key Trends and Opportunities to 2027
Global Tumor Infiltrating Lymphocyte (TIL) Key Trends and Opportunities to 2027

120 Pages
Type: Report
Code: QYRE-Auto-6V8373
Sat Dec 04 00:00:00 UTC 2021

Add to Cart

Global Neuroendocrine Carcinoma Treatment Key Trends and Opportunities to 2027
Global Neuroendocrine Carcinoma Treatment Key Trends and Opportunities to 2027

120 Pages
Type: Report
Code: QYRE-Auto-33S7899
Sat Dec 04 00:00:00 UTC 2021

Add to Cart